oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea
Orebro University Hospital. National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine.
National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden.
Infection IMed, AstraZeneca RandD Boston, Waltham, MA, United States.
Infection IMed, AstraZeneca RandD Boston, Waltham, MA, United States.
Show others and affiliations
2014 (English)In: Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, E-ISSN 1098-6596, Vol. 58, no 9, 5585-5588 p.Article in journal (Refereed) Published
Abstract [en]

We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (n = 250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.

Place, publisher, year, edition, pages
American Society for Microbiology , 2014. Vol. 58, no 9, 5585-5588 p.
National Category
Microbiology in the medical area Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:oru:diva-56454DOI: 10.1128/AAC.03090-14ISI: 000341262700070PubMedID: 24982070ScopusID: 2-s2.0-84906090956OAI: oai:DiVA.org:oru-56454DiVA: diva2:1082412
Note

Funding Agencies:

Örebro County Council Research Committee

Foundation for Medical Research at Örebro University Hospital, Sweden

Infection iMed, AstraZeneca Pharmaceuticals LP, Waltham, MA

Available from: 2017-03-16 Created: 2017-03-16 Last updated: 2017-03-16Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Jacobsson, SusanneGolparian, DanielJensen, Jorgen SkovUnemo, Magnus
By organisation
Orebro University Hospital
In the same journal
Antimicrobial Agents and Chemotherapy
Microbiology in the medical areaPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf